TNF Muteins and Uses Thereof
Summary
USPTO granted Patent US12605425B2 to Oxford University Innovation Limited for tumour necrosis factor (TNF) muteins that function as selective agonists of tumour necrosis factor receptor 1 (TNFR1). The patent covers compositions comprising these TNF muteins, methods of treating or detecting tumours, and related nucleic acids and host cells. This is a routine patent grant conferring exclusive rights to the assignee with no immediate compliance obligations for other parties.
What changed
USPTO granted Patent US12605425B2 to Oxford University Innovation Limited on 21 April 2026. The patent covers TNF muteins that are agonists selectively binding to tumour necrosis factor receptor 1 (TNFR1), along with compositions, methods of treating or detecting tumours, and related nucleic acids and host cells. 19 claims are included in the grant.
Third parties developing TNF-based therapeutics or TNFR1-targeted oncology products should review this intellectual property to assess potential freedom-to-operate implications. The assignee now holds enforceable patent rights in the United States covering the claimed muteins and their uses in anticancer applications.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TNF muteins and uses thereof
Grant US12605425B2 Kind: B2 Apr 21, 2026
Assignee
OXFORD UNIVERSITY INNOVATION LIMITED
Inventors
Nicola R. Sibson, Daniel C. Anthony, Sandra J. Campbell
Abstract
The present invention relates to tumour necrosis factor (TNF) muteins with improved properties, and in particular to TNF muteins which are agonists of, and bind selectively to, tumour necrosis factor receptor 1 (TNFR1). Compositions comprising the TNF muteins, which may additionally comprise appropriate anticancer agents or imaging agents are provided. The use of the muteins of the invention in methods of treating or detecting a tumour are also provided. The invention also provides nucleic acids (e.g. vectors) encoding the TNF muteins and host cells comprising the nucleic acids.
CPC Classifications
A61K 38/191 A61K 31/198 A61K 31/337 A61K 31/506 A61K 31/704 A61K 39/3955 A61K 49/105 A61K 38/00 A61K 31/711 A61P 35/00 C07K 14/525
Filing Date
2020-06-26
Application No.
17621711
Claims
19
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.